Lepr Deficiency Obesity
📧 Sign up to get email alerts when something new happens for Lepr Deficiency Obesity.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-07EMA Authorised: Imcivree (setmelanotide) — Rhythm Pharmaceuticals Netherlands B.V.
The European Medicines Agency authorised Imcivree (setmelanotide) for obesity, including rare genetic disorders of the melanocortin-4 recept…
-
FDA approval · 2025-08-21FDA Approved: IMCIVREE — Supplemental Application (Rhythm Pharmaceuticals, Inc)
The FDA approved a supplemental application for IMCIVREE (setmelanotide) submitted by Rhythm Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2024-07-10Clinical Trial Update: Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity [Phase 3]
Phase 3 trial update reports results for setmelanotide in pediatric patients with rare genetic obesity conditions, including Bardet-Biedl Sy…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity [Phase 2]
Phase 2 study evaluating LB54640 for genetic obesity shows ongoing investigation with unclear status.